The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol

dc.contributor.buuauthorGüneş, Adalet Meral
dc.contributor.buuauthorÖren, Hale
dc.contributor.buuauthorBaytan, Birol
dc.contributor.buuauthorBengoa, Şebnem Yılmaz
dc.contributor.buuauthorEvim, Melike Sezgin
dc.contributor.buuauthorGözmen, Salih
dc.contributor.buuauthorTüfekçi, Özlem
dc.contributor.buuauthorKarapınar, Tuba Hilkay
dc.contributor.buuauthorİrken, Gülersu
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1452-2021tr_TR
dc.contributor.researcheridHMO-7415-2023tr_TR
dc.contributor.scopusid24072843300tr_TR
dc.contributor.scopusid7004237315tr_TR
dc.contributor.scopusid6506622162tr_TR
dc.contributor.scopusid56183442400tr_TR
dc.contributor.scopusid36337796600tr_TR
dc.contributor.scopusid8240542100tr_TR
dc.contributor.scopusid25029172000tr_TR
dc.contributor.scopusid50161759700tr_TR
dc.contributor.scopusid6701779910tr_TR
dc.date.accessioned2024-02-29T12:31:02Z
dc.date.available2024-02-29T12:31:02Z
dc.date.issued2014-05-07
dc.description.abstractDramatic progress in the treatment of childhood acute lymphoblastic leukemia (ALL) has been achieved during the last two decades in Western countries, where the 5-year event-free survival (EFS) rate has risen from 30 to 85 %. However, similarly high cure rates have not always been achieved in all centers in developing countries due to limited sources. We evaluated the treatment results of the ALL-Berlin-Frankfurt-Munster (BFM) 95 protocol as used between 1995 and 2009 in the pediatric hematology departments of two university hospitals. A retrospective analysis of 343 children newly diagnosed with ALL (M/F 200/143, median age 6.8 years) was performed. The overall survival (OS) and EFS according to age, initial leukocyte count, immunophenotype, chemotherapy responses (on days 8, 15, and 33), and risk groups were analyzed by Kaplan-Meier survival analysis. Median follow-up time was 6.4 years. Complete remission was achieved in 97 % of children. Five-year EFS and OS were found to be 78.4 and 79.9 %, respectively. Children younger than 6 years old had significantly better EFS and OS (83.7 and 85.2 %) than children aged a parts per thousand yen6 years (71.4 and 72.8 %). Adolescents achieved 63 % EFS and 65 % OS. Patients who had initial leukocyte counts of < 20 Au 10(9)/L had better EFS and OS (82.2 and 84.6 %) than children with higher initial leukocyte counts (72.6 and 72.6 %). EFS for B-cell precursor and T-cell ALL was 81.5 and 66.7 %, respectively. Children with a good response to prednisolone on day 8 (87 %) achieved significantly better EFS and OS (81.2 and 81.9 % vs. 55.3 and 60.5 %). Children whose bone marrow on day 15 was in complete remission had higher EFS and OS (83.7 and 86.6.1 % vs. 56.4 and 61.5 %). Children in the standard-risk and medium-risk groups obtained statistically significantly higher EFS (95.5 and 82.7 %) and OS (97.7 and 82.3 %) compared to the high-risk group (EFS 56.3 %, OS 63.4 %). The relapse rate was 14.8 %. The median relapse time from diagnosis was 23.2 months. Death occurred in 69 of 343 patients (20.1 %). The major causes of death were infection and relapse. None of the patients died of drug-related toxicity. The ALL-BFM 95 protocol was applied successfully in these two centers. In developing countries in which minimal residual disease cannot be monitored, this protocol can still be used with high survival rates.en_US
dc.identifier.citationGüneş, A. M. vd. (2007). "The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol". Annals of hematology, 93(10), 1677-1684.tr_TR
dc.identifier.eissn1432-0584
dc.identifier.endpage1684tr_TR
dc.identifier.issn0939-5555
dc.identifier.issue10tr_TR
dc.identifier.pubmed24863691tr_TR
dc.identifier.scopus2-s2.0-85027930123tr_TR
dc.identifier.startpage1677tr_TR
dc.identifier.urihttps://doi.org/10.1007/s00277-014-2106-0en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s00277-014-2106-0en_US
dc.identifier.urihttps://hdl.handle.net/11452/40097en_US
dc.identifier.volume93tr_TR
dc.identifier.wos000341373300006tr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.journalAnnals of hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute lymphoblastic leukemiaen_US
dc.subjectSurvivalen_US
dc.subjectChemotherapyen_US
dc.subjectChildhooden_US
dc.subject5 consecutive trialsen_US
dc.subjectCareen_US
dc.subjectPrognostic-factorsen_US
dc.subjectSurvivalen_US
dc.subjectChildrenen_US
dc.subjectAdolescentsen_US
dc.subjectHematologyen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeChilden_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeDisease free survivalen_US
dc.subject.emtreeDrug screeningen_US
dc.subject.emtreeEpidemiologyen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeImmunophenotypingen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeKaplan meier methoden_US
dc.subject.emtreeLeukocyte counten_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeMulticenter studyen_US
dc.subject.emtreePrecursor cell lymphoblastic leukemia-lymphomaen_US
dc.subject.emtreePrecursor t-cell lymphoblastic leukemia-lymphomaen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeRisk assessmenten_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTurkeyen_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeAsparaginaseen_US
dc.subject.emtreeCyclophosphamideen_US
dc.subject.emtreeCytarabineen_US
dc.subject.emtreeDaunorubicinen_US
dc.subject.emtreeMercaptopurineen_US
dc.subject.emtreeOncoproteinen_US
dc.subject.emtreePrednisoloneen_US
dc.subject.emtreeVincristineen_US
dc.subject.mesh6-mercaptopurineen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAntineoplastic combined chemotherapy protocolsen_US
dc.subject.meshAsparaginaseen_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshCyclophosphamideen_US
dc.subject.meshCytarabineen_US
dc.subject.meshDaunorubicinen_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshDrug evaluationen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunophenotypingen_US
dc.subject.meshInfanten_US
dc.subject.meshKaplan-meier estimateen_US
dc.subject.meshLeukocyte counten_US
dc.subject.meshOncogene proteins, fusionen_US
dc.subject.meshPrecursor cell lymphoblastic leukemia-lymphomaen_US
dc.subject.meshPrecursor t-cell lymphoblastic leukemia-lymphomaen_US
dc.subject.meshPrednisoloneen_US
dc.subject.meshRemission inductionen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshRisk assessmenten_US
dc.subject.meshRisk factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.meshVincristineen_US
dc.subject.scopusResidual Neoplasm; Pediatrics; Pre B Lymphocyteen_US
dc.subject.wosHematologyen_US
dc.titleThe long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocolen_US
dc.typeArticleen_US
dc.wos.quartileQ2 (Hematology)en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections